Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Hester Biosciences Ltd Stock Analysis

Small Cap
Evaluated by 775 users | BSE: 524669 | NSE: HESTERBIO |
Pharmaceuticals & Drugs

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Capital Employed 13.34%14.16%14.35%12.93%16.76%18.09%18.3%22.54%14.48%18.49%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 48.365.169.190101123135171169208228
Y-o-Y Gr. Rt.-34.9%6.1%30.4%12.1%22.2%9.3%27%-1%23.1%-
Adjusted EPS (Rs.) 9.0911.3711.8614.1522.7729.3135.7650.9335.7451.5752.32
Y-o-Y Gr. Rt.-25.1%4.3%19.3%60.9%28.7%22%42.4%-29.8%44.3%-
Book Value per Share (Rs.) 70.5979.7989.3199.03117.93143.52171.72210.93238.72279.28293.67
Adjusted Net Profit 7.79.710.11219.424.930.443.330.443.945
Net Op. Cash Flow (Rs. Cr.) 12.713.411.420.418.627.632.336.225.840.1-
Debt to Cash Flow from Ops 1.291.83.111.92.071.431.321.061.850.4-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Hester Biosciences Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales 17.7%15.6%15.7%23.1%
Adjusted EPS 21.3%17.8%13%44.3%
Book Value per Share 16.518.817.617
Share Price 42.4% 27.1% 30.5% 45.2%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Equity (%) 14.3215.1214.0315.0320.9922.4222.6926.6215.919.9118.26
Operating Profit Margin (%) 39.1834.4236.6928.5233.3633.436.839.6731.1234.7333.68
Net Profit Margin (%) 16.0314.8514.6113.3719.220.2322.5725.3117.9521.0419.52
Debt to Equity 0.270.360.470.460.390.320.290.210.240.07-
Working Capital Days 316267290231229217220208261245-
Cash Conversion Cycle 246200202163160140140134164145-
Loading price chart...
Entity Percentage Holding
Promoters 53.73%
Institutions 0.69%
Non-Institutions 45.58%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Hester Biosciences Ltd's earnings have grown by 17.8%, whereas share price has appreciated 27.1% CAGR over the past five years, indicating the company’s share price is likely overvalued. However, for specific investment actions please consult your investment advisor.

Hester Biosciences Ltd share price has appreciated 42.4% annually (CAGR) over the past ten years.

Data is not available for this company.

Hester Biosciences was incorporated on April 29, 1987 as a Private Limited Company by the name of Hester Pharmaceuticals Limited. It was subsequently converted into a Public Limited Company on November 1, 1993. The company is engaged in the manufacturing of poultry vaccines. The company has been promoted by Rajiv D. Gandhi his brother Sanjiv D. Gandhi and Dr. Bhupendra V. Gandhi. The company changed its name to the present in 2008.

The company is a 100% biotech company producing animal

Hester Biosciences was incorporated on April 29, 1987 as a Private Limited Company by the name of Hester Pharmaceuticals Limited. It was subsequently converted into a Public Limited Company on November 1, 1993. The company is engaged in the manufacturing of poultry vaccines. The company has been promoted by Rajiv D. Gandhi his brother Sanjiv D. Gandhi and Dr. Bhupendra V. Gandhi. The company changed its name to the present in 2008.

The company is a 100% biotech company producing animal biologicals. Located near the city of Ahmedabad, in the state of Gujarat, in Western India, Hester has a state-of-the-art facility to produce live and killed (Inactivated) veterinary vaccines.

Production procedures for poultry vaccines based on in-house advanced capabilities are being followed in the areas of virus propagation in specific pathogen-free embryos, tissue culture, batch fermentation of bacteria, lyophilisation and emulsion preparation.

Hester on December 22, 2008 launched a poultry vaccine against Coryza disease in chicken, containing 3 serotypes – A, B & C.

Hester is the first company in India to manufacture the Coryza vaccine with 3 strains as against other companies manufacturing the vaccine with only 2 serotypes - A & C. Coryza disease is of economical importance to poultry farmers as it causes a drop in egg production in laying birds.

Hester currently manufactures 39 types of poultry vaccines against various poultry diseases.

Product range of the company includes:

  • Live Vaccines
  • Killed Vaccines
  • Diagnostic kits &  Seromonitoring services

Achievements/ recognition:

  • GMP and ISO 9001:2000 certified company
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback